Montelukast Sodium

製品コードS4211 バッチS421101

印刷

化学情報

Chemical Structure Synonyms MK0476 Storage
(From the date of receipt)		 3 years -20°C powder
化学式

C35H36ClNO3S.Na
分子量 608.17 CAS No. 151767-02-1
Solubility (25°C)* 体外 DMSO 100 mg/mL (164.42 mM)
Water 100 mg/mL (164.42 mM)
Ethanol 100 mg/mL (164.42 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Montelukast Sodium selectively antagonizes leukotriene D4 (LTD4) by binding to it so that block the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1. Montelukast improves macroautophagy but not the chaperone-mediated autophagy pathway. Solutions are unstable and should be fresh-prepared.
in vitro

Montelukast is a leukotriene receptor antagonist (LTRA) used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies. Montelukast blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus. This reduces the bronchoconstriction otherwise caused by the leukotriene, and results in less inflammation. [1]
in vivo

Montelukast (6 mg/kg, once per day for 20 d) significantly suppresses the increased eosinophils in BAL fluid and lung tissue, and increases IL-5 level in BAL fluid in OVA challenged mice. OVA challenge increases CysLT1 but decreases CysLT2 receptor mRNA expression. Montelukast inhibits the increased CysLT1 but not the reduces CysLT2 expression after OVA challenge. [2]

プロトコル(参考用のみ)

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

A targeted extracellular vesicles loaded with montelukast in the treatment of demyelinating diseases [ Biochem Biophys Res Commun, 2022, 594:31-37] PubMed: 35066377
Leukotriene receptor antagonists enhance HCC treatment efficacy by inhibiting ADAMs and suppressing MICA shedding [ Cancer Immunol Immunother, 2021, 70(1):203-213] PubMed: 32683508
Chronobiological activity of cysteinyl leukotriene receptor 1 during basal and induced autophagy in the ARPE-19 retinal pigment epithelial cell line [ Aging (Albany NY), 2021, 13(24):25670-25693] PubMed: 34919533
Studium vlivu vybraných inhibitorů proteinkináz na lékovou rezistenci zprostředkovanou cytochromy P450 [ CU Digital Repository, 2021, N/A] PubMed: None
Loss of N-Glycanase 1 Alters Transcriptional and Translational Regulation in K562 Cell Lines [ G3 (Bethesda), 2020, 4;10(5):1585-1597] PubMed: 32265286
A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab [ J Biol Chem, 2017, 292(9):3552-3567] PubMed: 28035003
A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. [ J Biol Chem, 2017, 292(9):3552-3567] PubMed: 28035003
Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia [ Leuk Lymphoma, 2017, 58(8):1903-1913] PubMed: 27931141

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。